Volume 5 Supplement 4

Abstracts from the 10th Symposium of Experimental Rhinology and Immunology of the Nose (SERIN 2015)

Open Access

Real-life effectiveness of a new allergic rhinitis therapy (MP29-02*) in Sweden

  • Pär Stjärne1,
  • Victoria Strand2,
  • Kaj Theman3,
  • Hans Christian Kuhl4 and
  • Anders Ehnhage1
Clinical and Translational Allergy20155(Suppl 4):P37

https://doi.org/10.1186/2045-7022-5-S4-P37

Published: 26 June 2015

Background

Over one quarter of individuals in Sweden report suffering from allergic rhinitis (AR), placing a considerable burden on both sufferers and society [1]. In clinical trials MP29-02* (a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP) in an advanced delivery system) provided complete/near complete symptom control in 1 of 6 moderate/severe seasonal AR (SAR) patients [2] and complete relief in 7 of 10 mild/moderate perennial AR (PAR) patients [3]. This study aimed to assess the effectiveness of MP29-02* in routine clinical practice.

Method

Results from Sweden (n=431) from a multinational, multicentre, prospective, observational study in adults/adolescents with moderate/severe AR for whom MP29-02* was prescribed according to SPC are reported. Patients had acute AR symptoms on Day 0. Intended study duration was 14 days. Patients assessed symptom severity using a visual analog score (VAS) from 0mm (not at all bothersome) to 100mm (very bothersome), in the AM prior to MP29-02* use, on Days 0, 1, 3, 7 and last day. This was described for the whole population and according to phenotype (i.e. SAR, PAR or SAR + PAR) and severity (less severe: baseline VAS=50-74mm; more severe: baseline VAS ≥75mm). Patients’ perceived level of disease control (i.e. well-, partly- and un-controlled) was assessed on Day 3.

Results

MP29-02* (1 spray/nostril bd; daily doses: AZE:548µg, FP:200µg) reduced VAS score from 67.9mm at baseline to 32.1mm by last visit, a shift of 36.1mm. Effectiveness was consistent regardless of phenotype or disease severity. Symptom burden reduced rapidly in the first days of treatment. 27% of all patients felt their symptoms were ‘well controlled’ and 43% felt their symptoms were ‘partly-controlled’ at Day 3. This perception of ‘well-controlled’ symptoms at Day 3 corresponded to an optimal VAS cut-off in Sweden of 39mm. On average patients treated with MP29-02* crossed this well-controlled VAS cut-off by Day 7.

Conclusion

MP29-02* provides effective and rapid symptom control in Swedish AR patients in a real-world setting irrespective of disease phenotype or severity, with responder rates higher than those observed in a clinical trial with moderate/severe AR patients, supporting MP29-02*’s position as the drug of choice for the treatment of AR.

*Dymista

Authors’ Affiliations

(1)
Dept of Clinical Science, Karolinska Institute
(2)
Astma och Allergimottagningen
(3)
Astma och Allergimottagningen
(4)
Meda

References

  1. Eriksson J, Ekerljung L, Ronmark E, Dahlen B, Ahlstedt S, Dahlen SE, et al: Clin Respir J. 2012, 6 (3): 159-68.View ArticlePubMedGoogle Scholar
  2. Meltzer E, Ratner P, Bachert C, Carr W, Berger W, Canonica GW, et al: Int Arch Allergy Immunol. 2013, 161 (4): 369-77.View ArticlePubMedGoogle Scholar
  3. Price D, Shah S, Bhatia S, Bachert C, Berger W, Bousquet J, et al: J Investig Allergol Clin Immunol. 2013, 23 (7): 495-503.PubMedGoogle Scholar

Copyright

© Stjärne et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement